Advertisement

Topics

Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More

06:50 EDT 14 Jun 2019 | Xconomy

Is one of the bigger biopharma acquisitions of the year in trouble? This past week, antitrust regulators once again delayed Roche’s planned $4.8 billion buyout of gene therapy developer Spark Therapeutics (NASDAQ: ONCE). The US Federal Trade Commission wants yet more information about the buyout, and overseas, the UK Competition and Markets Authority opened a […]

Original Article: Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More

NEXT ARTICLE

More From BioPortfolio on "Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.